Patients Often Lose in the Battle Between Pharmaceutical Companies and PBMs
Drug Topics
JULY 18, 2023
Over the last 5 years, both PBMs and drug manufacturers have implemented restrictions that raise patients’ cost burden for specialty medications.
Pharmaceutical Companies Related Topics 
FDA Approves Aprocitentan For Treatment of Uncontrolled High Blood Pressure
Drug Topics
MARCH 20, 2024
Aprocitentan (TRYVIO) from pharmaceutical company Idorsia demonstrated statistically significant and clinically meaningful reductions in blood pressure in combination with other antihypertensive therapies.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology
MAY 2, 2024
From Merck & Co to Sanofi, Pharmaceutical Technology lists the leading pharmaceutical companies spending the most on R&D in 2023.
Biologics contract manufacturing: A comprehensive guide for pharmaceutical companies
pharmaphorum
JULY 29, 2024
This comprehensive guide provides pharmaceutical companies with valuable insights into biologics contract manufacturing, including the role of CDMOs and key considerations for successful partnerships.
AstraZeneca Caps Out-of-Pocket Inhaler Costs at $35 Per Month
Drug Topics
MARCH 18, 2024
AstraZeneca is the second pharmaceutical company to cap out-of-pocket costs for eligible patients.
Opinion: How to stop the shift of drug discovery from the U.S. to China
STAT
MAY 6, 2025
pharmaceutical companies didn’t license any new drugs from China. Five years ago, U.S. By 2024, one-third of their new compounds were coming from Chinese biotechnology firms. Why are U.S. drugmakers sending their business to China?
Compounding 
142
142 
Opinion: Pharma’s ethically questionable sites essentially sell drugs directly to consumers
STAT
NOVEMBER 6, 2024
Some of the largest pharmaceutical companies in the U.S. This unprecedented move launches a new dystopic era: pharmaceutical companies as health care provider, no pesky physician middlemen needed. Want to self-prescribe a prescription drug? No problem!
STAT+: As pharmaceutical companies bemoan Medicare’s drug negotiations, hospitals and doctors stay mum
STAT
AUGUST 31, 2023
The pharmaceutical industry has been up in arms over Medicare’s first list of 10 prescription drugs that will be subject to negotiations. But other major parts of the health care industry — hospitals, doctors, and other providers — have refrained from either lending support or criticizing the government’s process.
Harm Reduction Therapeutics Begins Shipping OTC Naloxone Nasal Spray
Drug Topics
DECEMBER 21, 2023
The nonprofit pharmaceutical company plans to begin fulfilling orders for RiVive more broadly in early 2023 and will make it available across the US for free of charge or at a low breakeven cost.
STAT+: FDA tells drugmakers to redo studies run by a contract research firm due to data integrity issues
STAT
APRIL 4, 2025
During an April 2023 inspection at Raptim facilites in Nava Mumbai, India, FDA inspectors found “objectionable conditions” that led them to conclude the company falsified data in testing for multiple subjects and samples across multiple studies, according to a letter sent last week to the pharmaceutical companies.
FDA 142
142 
Wave sees RNA editing validation in early trial results
PharmaVoice
OCTOBER 17, 2024
The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.
A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology
PharmaVoice
SEPTEMBER 10, 2024
But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes. Over the past 10 years, PD1-blocking medicines have transformed cancer care.
Pharma’s big patent cliff, more obesity fundraising, and a failed ALS study
STAT
JANUARY 9, 2025
We chat about how pharmaceutical companies are navigating a looming patent cliff. We also talk about yet another obesity startup and a failed study from Google’s secretive anti-aging company Calico. And what are the hosts’ New Year’s resolutions? Read the rest…
High Demand Keeps Some Diabetes Medications in Short Supply
Drug Topics
FEBRUARY 8, 2023
Pharmaceutical companies are experiencing supply chain disruptions and shortages because of the popularity of diabetes drugs used for weight loss.
STAT+: Wyden claims Pfizer used a ‘colossal’ scheme to avoid paying billions in U.S. taxes
STAT
MARCH 27, 2025
lawmaker described as possibly the “largest tax-dodging scheme” by a pharmaceutical company in history, Pfizer sold $20 billion in medicines to U.S. In what one U.S.
STAT+: Pharma still ‘falling short’ in providing access to low- and middle-income countries, analysis finds
STAT
NOVEMBER 19, 2024
Although more pharmaceutical companies are tailoring their business models to focus on low-income countries, a new analysis finds that overall industry efforts remain limited and patient access continues to suffer as a result.
STAT+: Truveta enlists health systems, drugmakers to launch ambitious new genomic database
STAT
JANUARY 13, 2025
The genetic data, cross-referenced with the patients’ de-identified medical records, will be available for purchase for researchers and life sciences companies. Pharmaceutical company Regeneron has invested $119.5
Medical Records 131
131 
Generic Tiotropium Bromide Inhalation Powder For Treatment of COPD Now Available in US
Drug Topics
NOVEMBER 20, 2023
The capsule was developed by the pharmaceutical company Lupin and is a generic equivalent to Boehringer Ingelheim’s Spiriva HandiHaler.
STAT+: European regulators approve $16.5 billion deal for Novo Holdings to buy Catalent
STAT
DECEMBER 6, 2024
The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of Novo Nordisk, one of the largest pharmaceutical companies, would pay $16.5 billion for Catalent, a leading contract drug manufacturer.
STAT+: Young biotech venture firm raises $500 million for its second fund
STAT
DECEMBER 9, 2024
Well, in Dimension’s case, they end up investing in some buzzy AI startups, counseling pharmaceutical companies, ribbing one another about expense reports, and — as of Monday — are able to raise $500 million for their second fund.
STAT+: Why Orexo is abandoning a digital therapeutic for depression
STAT
DECEMBER 3, 2024
Swedish pharmaceutical company Orexo will no longer pursue an app for treating depression after many years of struggling to sell it. Orexo announced this week that it will no longer license the product, called Deprexis, from German manufacturer GAIA.
STAT+: U.K. lawmaker wants regulators to probe pharma companies over ‘misleading’ Covid-19 vaccines statements
STAT
FEBRUARY 14, 2025
Parliament is calling for regulators to audit pharmaceutical companies that have made misleading statements to the public about their Covid-19 vaccines. A member of the U.K. And the move comes after Moderna was chastised for the second time in five months by a U.K.
Vaccines 112
112 
STAT+: Sanofi plans to change payment terms for 340B hospitals
STAT
NOVEMBER 22, 2024
The battle over prescription drug discounts offered to hospitals under a federal program escalated as Sanofi became the third pharmaceutical company to disclose plans to change the way it will make payments.
Hospitals 112
112 
Artificial Intelligence is Changing the Face of Pharmacovigilance
Pharmacy Times
OCTOBER 17, 2022
Pharmaceutical companies are looking into AI as the new method to not only reduce research and development costs, but also prevent costly errors.
STAT+: Belgian anti-trust authorities probe Roche for allegedly delaying biosimilars of two cancer meds
STAT
MARCH 17, 2025
In a brief statement , the Belgian Competition Authority alleged that Roche offered financial incentives to hospitals between 2017 and 2020 to deter them from considering competitive bids from other pharmaceutical companies that could supply similar medicines.
STAT+: Tapping the potential of GLP-1 drugs requires integrated care and overcoming inequities, executives say
STAT
MARCH 20, 2025
And reminiscent of a modern-day gold rush, there is now a headlong race among a growing number of pharmaceutical companies to determine how many other maladies the drugs may be capable of treating.
Does your copay program factor in differences across specialties? GoodRx analysis shows it should.
PharmaVoice
OCTOBER 17, 2022
To address this gap, GoodRx is partnering with pharmaceutical companies to improve cost transparency and communication between patients and providers. New findings reveal an out-of-pocket cost gap between brand-name and generic prescriptions.
A Win for Indiana Patients: “Share the Savings” Legislation Now Law
PhRMA
MAY 8, 2023
Negotiations between pharmaceutical companies, health insurers, PBMs and others result in significant rebates and discounts that totaled $236 billion in 2021. However, those savings aren’t always shared with patients, which means there are patients who end up paying more for their medicine than their insurer and PBM.
Novo Nordisk industry membership reinstated
European Pharmaceutical Review
MARCH 18, 2025
Novo Nordisk has regained full membership with the Association of the British Pharmaceutical Industry (ABPI), following suspension in 2023. This action resulted after the pharmaceutical company made serious breaches of the ABPI Code of Practice in 2021.
Is the flu shot market a slam dunk for mRNA vaccines? Experts aren’t so sure
STAT
DECEMBER 5, 2023
And pharmaceutical companies that learned of the vaccine-making power of the messenger RNA platform during the Covid-19 pandemic need new markets for their technology. Here are two things that are true. The world needs more effective flu vaccines. Read the rest…
Vaccines 145
145 
Weight-loss drug firm accused of prioritising profits after halting insulin pen production
The Guardian - Pharmaceutical Industry
OCTOBER 16, 2024
Novo Nordisk’s decision will force people in developing countries to use outdated glass vials and syringes, warn campaigners The pharmaceutical company behind injectable weight-loss drugs has been accused of prioritising profits over the health of people in developing countries by halting production of its insulin pens.
Opinion: The Pandemic Treaty will succeed only with investment to build strong health systems
STAT
MAY 31, 2024
The vested interests of pharmaceutical companies, lobbying groups, and conservative British broadcaster Nigel Farage bleating about “defending sovereignty” are threatening to derail the treaty process entirely. The treaty has been beset by delay and misinformation.
What can pharma companies do to quicken the pace of digital disruption?
pharmaphorum
JUNE 10, 2024
Discover how pharmaceutical companies can leverage digital technologies to accelerate innovation and disrupt the industry. Learn about regulatory considerations and engagement with healthcare professionals (HCPs) for successful digital transformation.
Listen: Biotech layoffs, founder-focused VC, & a big pharma exit
STAT
JULY 11, 2024
Why are pharmaceutical companies cutting more staff than cash-strapped biotechs? And who will Pfizer scout out as its next science chief? STAT’s West Coast biotech reporter Jonathan Wosen joins “The Readout LOUD” to discuss what’s driving workforce cuts. Read the rest…
STAT+: Pfizer plans to depart BIO
STAT
DECEMBER 5, 2023
The departure is a blow to BIO, which represents members ranging from small biotech startups to massive pharmaceutical companies. WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources familiar with the decision.
Long-overlooked scientist shares Lasker Award with other GLP-1 researchers
STAT
SEPTEMBER 19, 2024
Read the rest…
STAT+: Pharma execs donated more to Democrats in campaign’s final stretch
STAT
OCTOBER 21, 2024
WASHINGTON — Most executives at pharmaceutical companies haven’t directly donated to political candidates over the final stretch of the 2024 campaign. But those who have largely gave to Democrats.
STAT+: Generic drugmakers win a long-running battle with California over a law to ban pay-to-delay deals
STAT
FEBRUARY 18, 2025
California officials were dealt a setback by a federal judge who ruled that a controversial law banning so-called pay-to-delay deals between pharmaceutical companies is, in part, unconstitutional and so cannot be enforced against agreements that had no link to the state. In his ruling , U.S.
Triumphing in trials
pharmaphorum
JANUARY 2, 2025
The challenges facing oncology clinical trials are multifaceted, but there is a clear opportunity for pharmaceutical companies to rethink their approach to clinical research, and prioritise the patient from the beginning.
Watch: How drug patents pave the way to profit
STAT
AUGUST 8, 2024
Discovering a new drug is a big win for a pharmaceutical company, but selling it for lots of money with no competition? This is Part 3 of “Behind the Counter,” an in-depth video series demystifying the complex world of patents and drug pricing. The cherry on top. Read the rest…
To fight rare diseases, win the data battle first
pharmaphorum
DECEMBER 18, 2023
This article explores how pharmaceutical companies are leveraging AI and focusing on orphan drugs to tackle rare diseases. To effectively combat rare diseases, it is essential to prioritise the collection and analysis of data.
How biometrics applications are contributing to clinical trial diversity
pharmaphorum
JULY 31, 2024
Ensuring equitable access to medications remains a fundamental commitment for many pharmaceutical companies to their customers, patients, and stakeholders. However, there has been a discernible shift recently in the timing of access discussions.
STAT+: FDA approves a gene therapy for the inherited bleeding disorder hemophilia B
STAT
NOVEMBER 22, 2022
The one-time treatment, called Hemgenix, was developed by the Dutch biotech company UniQure and will be marketed by CSL Behring, an Australian pharmaceutical company. The Food and Drug Administration on Tuesday approved the first gene therapy to treat people with hemophilia B, an inherited bleeding disorder.
Pain is reduced by almost half with cannabis-based medicines – report finds
Outsourcing Pharma
MARCH 11, 2024
On March 7, Celadon Pharmaceuticals plc, a leading UK-based pharmaceutical company specializing in cannabis-based medicines, unveiled promising findings from an early economic analysis of its chronic pain clinical trial, dubbed CANPAIN.
Let's personalize your content